Sandoz's Free LSD Supply Policy

Sandoz's Free LSD Supply Policy turned a baffling new compound into a widely accessible object of investigation: from 1949 to 1966, Sandoz offered researchers as much LSD as they requested, free of charge. By treating even therapists who promised to report their clinical observations as researchers, the company helped set off the first wave of psychedelic research. The policy expanded who could investigate LSD and where, but it did not make the resulting experiences or their interpretations straightforward. Its abrupt end in 1966, as controversy gathered around the drug, exposed how dependent that research network was on a single source of supply.

An Unusual Research Offer

After LSD’s discovery, Sandoz hoped that someone, somewhere, would find a commercial application for its powerful new compound. Rather than confine access to a small group of institutional investigators, the company made a broad offer: researchers could obtain whatever amount they requested without charge. The definition of researcher was deliberately expansive. A therapist who undertook to write up clinical observations could qualify, bringing clinical practice into the circle of investigation alongside more conventionally organized research.

The policy’s significance lay in the combination of scale and openness. Free provision lowered a practical barrier to experiments, while the promise to document observations offered Sandoz a possible return in knowledge rather than immediate payment. The arrangement did not specify a single question to be answered. Researchers encountered LSD as a possible aid to psychotherapy and as an experience whose meaning was still uncertain; across the field, people struggled to decide how its effects fitted existing accounts of the mind. Sandoz’s offer effectively invited a dispersed research community to explore those possibilities.

Access Becomes a Network

The policy’s reach can be seen in the movement of both LSD and clinical know-how among researchers. By the late 1950s, Al M. Hubbard was carrying supplies of Sandoz LSD and therapeutic advice between centers across North America. He worked with Humphry Osmond and Abram Hoffer in Weyburn, met with R. Gordon Wasson in Manhattan, and conducted sessions with Betty Eisner, Sidney Cohen, and Oscar Janiger in Los Angeles. In Vancouver, he helped establish LSD treatment for alcohol dependence at Hollywood Hospital, which dedicated a wing to the work; he also flew Hollywood celebrities there discreetly and established two other Canadian treatment facilities.

This circulation was more than a chain of deliveries. Hubbard shared techniques as he moved among groups, connecting clinical work that might otherwise have remained local. Myron Stolaroff’s experience shows how such connections reached beyond hospitals: after an LSD session guided by Hubbard, Stolaroff shared his interest with colleagues at Ampex, where Don Allen and Willis Harman joined discussions of LSD and human potential. Hubbard later guided group members and trained them to guide others. In 1961, Stolaroff left Ampex and established the International Foundation for Advanced Study with Harman; the foundation obtained a research permit and began work with LSD and Mescaline supplied through Hubbard. Sandoz’s free-supply policy did not itself prescribe these projects, but its availability helped make an interlinked field of clinical, spiritual, and creativity-oriented inquiry possible.

What the Policy Could Not Settle

Wider access did not produce a single agreed account of what LSD did. Psychedelic experiences were highly responsive to expectation: people who anticipated spiritual revelation, temporary madness, or access to the unconscious might experience the drug through precisely those frames. Aldous Huxley’s writing helped shape an Eastern-inflected interpretation of LSD from the mid-1950s onward, and Timothy Leary and his Harvard colleagues amplified that orientation in a manual based on the Tibetan Book of the Dead. The policy enlarged the number of settings in which LSD could be tried; it could not separate the drug’s effects from the expectations and interpretations surrounding each session.

That difficulty became a challenge to professional boundaries. The high-dose psychedelic approach associated with Humphry Osmond, Al M. Hubbard, and Aldous Huxley proposed a single transformative session rather than extended weekly treatment, and it carried spiritual practices into a field increasingly committed to biochemical accounts of the mind. Charles Grob later characterized this approach as applied mysticism. Researchers also faced a basic problem of evaluation: participants and guides could often tell whether LSD or a placebo had been given, while setting, therapist presence, and expectation all complicated attempts to isolate the drug’s effect. The supply policy enabled extensive exploration, but the resulting evidence raised questions about what counted as a drug effect, a therapeutic intervention, or a spiritual experience.

A Field Built on Fragile Access

Sandoz’s offer remained more or less unchanged from 1949 through 1966, and the book identifies it as a major cause of the first wave of psychedelic research. That wave depended not only on curious investigators but on a company willing to supply a controversial compound broadly and without charge. When controversy mounted around LSD, Sandoz abruptly withdrew Delysid from circulation. The decision brought the policy to an end and helped close the period of research it had helped set in motion.

The consequences outlasted the offer itself. Later accounts of underground psychedelic therapy traced professional lineages to first-wave researchers, including Al M. Hubbard and Leo Zeff. Myron Stolaroff argued that the research revived in universities from the late 1990s had developed partly from the anecdotal work of underground therapists as well as from the earlier research. Some underground guides were later recruited to train guides for university trials, and researchers at Johns Hopkins consulted underground guides about their musical practices. This continuity was not a simple institutional succession: it depended on knowledge carried through people, training, and practice after sanctioned research had stopped.

The policy therefore marks both an opening and a vulnerability in psychedelic research. By placing LSD in the hands of a broad range of investigators and therapists, Sandoz helped generate a diverse body of clinical and experiential inquiry. But the breadth of the work also made the boundary between medicine, spirituality, and cultural experimentation harder to police, while the eventual withdrawal of supply showed how quickly a research field could be curtailed when its source of access disappeared.